 |
PRELIMINARY PROGRAM
Last updated 6 September 2004 |
|
Educational Objectives
Upon completion of this workshop, participants should be able to:
 Describe the use of in
vivo MR methods in oncology drug development;
Define the potential role of
the in vivo MR methods in oncology drug development;
Describe recent advances in
molecular imaging of cancer;
Identify the present state
of targeted contrast agent use in molecular and cellular imaging of cancer;
Describe the information
provided by in vivo MR methods in the assessment of cancer treatment
response and its associated toxicity
Predict the nature of future
MR methods used in experimental and clinical imaging of cancer. |
| Friday, 15 October |
|
17:00 - 19:00 |
Registration and Poster Set-up |
| Saturday, 16 October |
07:00 |
Breakfast, Registration, Poster Set-up |
09:00 |
Welcome
- Zaver Bhujwalla, Ph.D., Johns Hopkins University, Baltimore, Maryland, USA
- Martin O. Leach, Ph.D., Royal Marsden NHS Trust, Institute of Cancer
Research, Surrey, England, UK
|
|
|
09:10 |
SESSION I: MRI and MRS in Drug Discovery and
Development
Chair: Jeffrey L. Evelhoch, Ph.D., Amgen, Inc., Thousand Oaks, CA
USA |
|
09:15 |
Overview of the Oncology Drug Development Process from
Discovery to Market
Teresa M. McShane, Ph.D., D.V.M., Pfizer Inc., Groton, Connecticut, USA |
|
09:40 |
Clinical Drug Development Process, Including the Role of
Imaging
Gordon Jayson, F.R.C.P., Ph.D., Christie Hospital, Manchester, England,
UK |
10:05 |
Break |
| |
SESSION I, continued |
| 10:20 |
Past, Present and Future Role of MR in
Discovery/Preclinical Drug Development
Robert J. Gillies, Ph.D., University of Arizona,
Tucson, Arizona, USA |
|
10:45 |
Value of Translational Studies to the Drug
Development Process
John C. Waterton, Ph.D., AstraZeneca, Cheshire,
England, UK |
|
11:10 |
Panel Discussion (Session I Speakers) |
|
11:40 |
Proffered papers
(15 minutes per talk)
- MRS Assessment on Metabolic Response to a Novel
EGFR Inhibitor ZD1839 in Colon Cancer Cells
Jelena Miljus, University of Colorado Health
Sciences Center, Dept. of Anesthesiology, Denver, CO, USA
- Effects of an Anti-Angiogenic and Anti-Tumour
Antibody on Tumour Vasculature Determined by Dynamic Contrast Enhanced
MRI
Inna V. Linnik, University of Manchester, Manchester, England, UK
|
|
12:10 |
Lunch |
13:30 |
Negendank Memorial Lecture: Advanced
MRS and MRI Methods in Clinical Assessment of Cancer Treatment
Michael Garwood, Ph.D., CMRR, University of
Minnesota, Minneapolis, MN, USA |
|
14:15 |
Poster Session I: Functional and Molecular
Assessment of Cancer by MRI |
|
15:45 |
Break |
|
16:00 |
SESSION
II: Clinical
Oncology MR Trials
Chair: Martin O. Leach, Ph.D., Royal Marsden
NHS Trust, Institute of Cancer Research, Surrey, England, UK |
|
16:15 |
What is Needed from Biomarkers in Modern Cancer Drug
Development: Acceleration, Enlightenment and the Pharmacological Audit Trail
Paul Workman, Ph.D., Cancer Research UK Centre for
Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey,
England, UK |
|
16:45 |
The Role of Pharmacodynamic Biomarkers in Early Cancer
Clinical Trials
Ian Judson, M.A., M.D., M.R.C.P.,
Cancer Research UK Centre for
Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey,
England, UK |
|
17:15 |
Clinical evaluation of antivascular drugs by
dynamic MRI: considerations for early multicentre trials
Anwar R. Padhani,
M.R.C.P., F.R.C.R., Mount Vernon Hospital, Paul Strickland
Scanner Centre, Northwood, England, UK |
|
17:45 |
Adjournment |
18:30 |
Dinner |
| Sunday, 17 October |
|
07:00 |
Breakfast |
|
08:30 |
SESSION
III: Molecular and Cellular
Imaging of Cancer
Chair:
Risto A. Kauppinen, M.D., Ph.D.,
University of Manchester, Manchester, England, UK |
|
08:45 |
Towards MRI Visualization of Gene Expression and
Enzymatic Activity in Tumor Angiogenesis
Michal Neeman, Ph.D., The Weizmann Institute of
Science, Rehovot, Israel |
|
09:15 |
Hypoxia in tumours. What can MRI tell us?
Prof. Ian J. Stratford, University of Manchester,
School of Pharmacy, Manchester, England, UK
Catharine West, University of Manchester, School of Pharmacy, Manchester,
England, UK |
|
09:50 |
Proffered Papers
(15 minutes per talk)
- 1H Magnetic Resonance Spectroscopic
Imaging of Phopholipase Activity in Rat Bliomas
In Vivo
Timo Liimatainen, A.I. V. Institute/University of Kuopio, Department
of Biomedical NMR, Kuopio, Finland
- Combined Metabolic, Pathologic, and Genetic
Analysis of Human Prostate Tissues: Quantitative Assessment of
Histopathologic and mRNA Integrity after HR-MAS Spectroscopy
Mark G. Swanson, Ph.D., University of California at San Francisco,
San Francisco, CA, USA
- Multimodality Imaging of Phospholipase Activity in
Prostate Cancer Cells Treated with Differentiating Agents
Matthew Milkevitch, Ph.D., University of Pennsylvania Medical
College, HUP Radiology, Philadelphia, PA, USA
|
|
|
10:35 |
Break |
|
|
SESSION
III, continued |
|
10:45 |
Molecular and Functional Imaging of Cancer
Zaver Bhujwalla, Ph.D., Johns Hopkins University,
Baltimore, Maryland, USA |
|
11:10 |
Proffered Papers
(15 minutes per talk)
- Magnetic Resonance Spectroscopy Confirms the
Mechanism of Action of the Choline Kinase Inhibitor MN58b in Human
Breast Cancer Cells
Nada M. S. Al-Saffar, Ph.D., Royal Marsden Hospital, CRC Clinical
MR Research Group, Sutton, England, UK
- Choline Kinase Knock-down in Human Breast Cancer
Xenografts Monitors by 31P MR Spectroscopy
Kristine Glunde, Ph.D., Johns Hopkins University, Radiology
Department - NMR Research, Baltimore, MD, USA
- Lymphatic Drainage/Sentinel Node Imaging of Breast
Cancer in Mice using Micro-Magnetic Resonance Mammo-Lymphangiography
with Nano-Size Contrast Agents with Various Molecular Diameters
Hisataka Kobayashi, M.D., Ph.D., MIP/CCR/NCI/NIH, Bethesda, MD, USA
|
|
|
12:00 |
Lunch |
|
13:30 |
SESSION
IV: Targeted Contrast Agents
in MRI of Cancer
Chair: Silvio Aime, University of Torino, Department of Chemistry,
Torino, Italy |
|
13:50 |
Models of Cancer: From Mouse to Man
Joel R. Garbow, Ph.D., Washington University, St.
Louis, Missouri, USA |
|
14:20 |
Detecting Early Responses to Therapy Using
Magnetic Resonance Imaging and Spectroscopy
Kevin M. Brindle, D.Phil, University of Cambridge,
Cambridge, England, UK |
|
14:50 |
Contrast Agents for Molecular and Cellular MR
Imaging of Cancer
Jeff W.M. Bulte, Ph.D., Johns Hopkins University,
Baltimore, Maryland, USA |
|
15:15 |
Poster Session II:
MRS of Cancer |
|
16:45 |
Roundtable Discussion: Prospects of Molecular Imaging
by MR: How Specific can MRI/MRS Become in Detection of Cancer Diagnosis and
Treatment Response in Vivo?
Discussion Leaders:
- Jerry D. Glickson, Ph.D., University of
Pennsylvania, Philadelphia, Pennsylvania, USA
- Sarah J. Nelson, Ph.D., University of California at
San Francisco, CA, USA
|
|
18:30 |
Dinner Banquet |
| Monday, 18 October |
|
07:00 |
Breakfast |
|
08:30 |
SESSION
V: MRI and MRS in the
Assessment of Therapeutic Response and Toxicity
Chair: Pat Price, M.A., M.D., F.R.C.R., F.R.C.P., Christie Hospital,
Radiation Oncology, Manchester, England, UK |
|
08:45 |
Monitoring Anticancer Drugs by MRS and Metabolic
Profiling
John R. Griffiths, M.B.B.S., D.Phil., St. George's
Hospital Medical School, London, England, UK |
|
09:15 |
MRI and Spectroscopic Methods for Detecting
Therapeutic Response
Harish Poptani, Ph.D., University of Pennsylvania,
Philadelphia, Pennsylvania, USA |
|
09:45 |
Break |
|
10:15 |
Diffusion
Tensor MR Imaging - A New Tool for the Assessment Treatment-Induced
Neurotoxicity?
Pek-Lan Khong, M.D., The University of Hong Kong, Hong
Kong, China |
|
10:50 |
Proffered Papers (15 minutes per
talk)
- Neurocognitive correlates of white matter volume in
children surviving cancer
Wilburn E. Reddick, Ph.D., St. Jude Children's Research Hospital,
Department of Diagnostic Imaging, Memphis, TN, USA
- Long term evolution of apparent diffusion
coefficient and choline MR signal in glioblastoma multiforme following
fractionated external beam radiation therapy
Jeffry R. Alger, Ph.D., David Geffin School of Medicine at UCLA,
Ahmanson-Lovelace Brain Mapping Center, Los Angeles, CA, USA
- Improved delineation of glioma margins using
diffusion tensor imaging: an image-guided biopsy study
Stephen J. Price, F.R.C.S., Addenbrooke's Hospital, Academic
Neurosurgery Unit, Cambridge, England, UK
- Late tissue effects following radiotherapy of the
prostate measured with quantitative MRI
David L. Buckley, Ph.D., University of Manchester, ISBE,
Manchester, England, UK
- Relation between dynamic gadolinium-DTPA uptake and
response to chemotherapy in colorectal liver metastases
Hanneke W. M. van Laarhoven, M.D., M.A., UMC Nijmegen, Department
of Medical Oncology, Nijmegen, Netherlands
- Pharmokinetic analysis of dynamic breast cancer MRI
and DUR analysis of FDG-PET. Effects of Registration on observed
correlation
Scott Ian Kay Semple, Ph.D., University of Aberdeen, Department of
Biomedical Physics, Aberdeen, Scotland, UK
|
|
|
12:20 |
Adjournment |
 |